Publications
Explore the scientific publications supporting FINNCURE's
technology platform.
Validation of Lung-Targeted Delivery
Evaluation of inhaled functionalized particles in mice showed efficient lung delivery, prolonged retention, minimal off-target distribution, and good pulmonary tolerability.
Highlights
- Efficient delivery to the lungs following inhalation
- Minimal distribution to non-target organs
- No significant lung inflammation or tissue damage observed
Zhang, P., Niemelä, E., Filis, P., Sorvisto, P., Virtanen, J., & Santos, H. A. (2026). Inhaled Virus-Mimicking Particles Elicit Dose-Dependent Immune Response against SARS-CoV-2 with Sex-Bias ACE2 Activity in Mice. Nano Letters, 26(22), 7227-7234.
Validation of Platform Technology
Peer-reviewed validation of FINNCURE's platform, from surface engineering and receptor targeting to biological efficacy and reproducible manufacturing.
Highlights
- Highly reproducible particle manufacturing
- Strong ACE2 receptor binding affinity and enhanced cellular uptake
- Significant suppression of SARS-CoV-2 pseudoviral entry in vitro
- Extremely low cytotoxicity across tested cell models
Zhang, P., Niemela, E., López Cerdá, S., Sorvisto, P., Virtanen, J., & Santos, H. A. (2024). Host-directed virus-mimicking particles interacting with the ACE2 receptor competitively block coronavirus SARS-CoV-2 entry. Nano Letters, 24(14), 4064-4071.